TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms

TRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push that number even higher.